Central Nervous System International Prognostic Index (CNS-IPI)

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
cns ipi assessment
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–1
  • Intermediate Risk2–3
  • High Risk4–6
Direct Clinical Answer

The Central Nervous System International Prognostic Index (CNS-IPI) calculator is designed for bedside predicting the risk of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy in clinical practice. The resulting score directly guides clinician decision-making regarding.

Clinical Guidelines & Evidence

Prognostic scoring system that predicts the risk of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy. Helps identify patients who may benefit from CNS-directed prophylaxis and guides treatment planning decisions.

Clinical Indication

The Central Nervous System International Prognostic Index (CNS-IPI) is indicated for bedside clinical practice to support Prognostic scoring system that predicts the risk of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy. Helps identify patients who may benefit from CNS-directed prophylaxis and guides treatment planning decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Score should be calculated at initial diagnosis before treatment initiation.

Formula & Variables:

CNS-IPI Score = Age >60 years (1) + LDH >normal (1) + ECOG PS >1 (1) + Ann Arbor stage III/IV (1) + >1 extranodal site (1) + Kidney/adrenal involvement (1). Total range: 0-6 points.

Input Parameters

NameTypeRequiredDescription
age_over_60stringYesPatient age greater than 60 years
elevated_ldhstringYesLactate dehydrogenase (LDH) level above normal laboratory range
ecog_performance_status_over_1stringYesECOG Performance Status greater than 1 (moderate to severe limitation of activity)
advanced_stagestringYesAnn Arbor stage III or IV disease (advanced stage)
multiple_extranodal_sitesstringYesMore than 1 extranodal disease site involved
kidney_adrenal_involvementstringYesInvolvement of kidney and/or adrenal gland

Score Interpretation & Guidance

RangeStageDescription
0–1Low RiskVery low CNS relapse risk
2–3Intermediate RiskLow to moderate CNS relapse risk
4–6High RiskHigh CNS relapse risk

Evidence-Based References (EBM)

  • Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. J Clin Oncol. 2016 Sep 10;34(26):3150-3156. doi: 10.1200/JCO.2015.65.6520.DOI: 10.1200/JCO.2015.65.6520
  • Ma'koseh M, Rahahleh N, Abdel-Razeq H. Impact of Central Nervous System International Prognostic Index on the Treatment of Diffuse Large B Cell Lymphoma. Cureus. 2021 Aug 13;13(8):e17016. doi: 10.7759/cureus.17016.DOI: 10.7759/cureus.17016
  • Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016 Apr 28;127(17):2182-8. doi: 10.1182/blood-2015-10-676700.DOI: 10.1182/blood-2015-10-676700

Related calculators